These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 4154088
1. Delayed secondary disease in mice after early or late therapy with anti-thymocyte serum. Kinnamon KE, Blackwell LH, Ledney GD. Exp Hematol; 1973; 1(4):202-14. PubMed ID: 4154088 [No Abstract] [Full Text] [Related]
8. Of mice and men in bone marrow transplantation. Mathé G, Schwarzenberg L, Halle-Pannenko O, Abuaf N, Pouillart P. Transplant Proc; 1977 Mar; 9(1):155-68. PubMed ID: 17189 [No Abstract] [Full Text] [Related]
9. A comparison of hematopoiesis after treatment with antithymocyte serum and erythropoietin. Kinnamon KE, Blackwell LH, Ledney GD. Exp Hematol; 1974 Mar; 2(4):204-11. PubMed ID: 4616844 [No Abstract] [Full Text] [Related]
10. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM, Waller EK. Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [Abstract] [Full Text] [Related]
11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S. J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666 [Abstract] [Full Text] [Related]
12. [Use of heterologous antireceptor antibodies for specific reversal of acute homologous disease in mice]. Nesterenko VG, Gruner Sh, Rubakova EI, Babadzhanov AS. Biull Eksp Biol Med; 1980 Nov 15; 90(11):588-90. PubMed ID: 7192584 [Abstract] [Full Text] [Related]
13. Possibility of three distinct and separable components to fatal graft-vs-host reaction. Okunewick JP, Meredith RF, Raikow RB, Buffo MJ, Jones DL. Exp Hematol; 1982 Mar 15; 10(3):277-91. PubMed ID: 7040093 [No Abstract] [Full Text] [Related]
14. Graft versus host disease prophylaxis today. Martelli MF, Aversa F. Bone Marrow Transplant; 1991 Mar 15; 7 Suppl 2():112-6. PubMed ID: 1908726 [No Abstract] [Full Text] [Related]
15. Bone marrow transplantation. Influence of T lymphocytes on the process of differentiation and proliferation of bone marrow cells. Vitale B, Burek V, Plavljanić D. Transplant Proc; 1977 Mar 15; 9(1):269-72. PubMed ID: 17193 [No Abstract] [Full Text] [Related]
16. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Johnson BD, Drobyski WR, Truitt RL. Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480 [Abstract] [Full Text] [Related]
17. Prevention of graft-versus-host disease by Fab fragments derived from ALG. Richie ER, Gallagher MT, Trentin JJ. Transplant Proc; 1973 Mar 15; 5(1):873-6. PubMed ID: 4144467 [No Abstract] [Full Text] [Related]
18. H-2 restriction of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers in mice. Korngold R, Sprent J. Transplant Proc; 1981 Mar 15; 13(1 Pt 2):1217-9. PubMed ID: 7022928 [No Abstract] [Full Text] [Related]
19. GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation. Rodt H, Kolb HJ, Netzel B, Rieder I, Janka G, Belohradsky B, Haas RJ, Thierfelder S. Transplant Proc; 1979 Mar 15; 11(1):962-6. PubMed ID: 377731 [No Abstract] [Full Text] [Related]